Chromophobe Renal Cell Carcinoma with Sarcomatoid Differentiation

Overview

Journal J Kidney Cancer VHL

Date 2023 Jul 13

PMID 37441361

Authors

Benjamin J Lichtbroun

Brian Shinder

Tina Gowda Sara

Arnav Srivastava

Biren Saraiya

Tina M Mayer

Ryan Cristelli

Evita Sadimin

Robert E Weiss

Eric A Singer

Affiliations

Soon will be listed here.

Abstract

Chromophobe renal cell carcinoma (chRCC) is one of the less common types of kidney cancer and generally portends a more favorable prognosis. RCC with sarcomatoid differentiation has a more aggressive clinical course with poor outcomes. Four cases of chRCC with varying degrees of sarcomatoid differentiation were retrospectively reviewed at our institution, and clinicopathologic data as well as clinical courses were reported. Patients with higher degrees of sarcomatoid differentiation and larger tumors at presentation generally had and worse overall survival. chRCC with sarcomatoid differentiation portends a poor prognosis with limited data on systemic treatment options for metastatic disease.

References

Roubaud G, Gross-Goupil M, Wallerand H, De Clermont H, Dilhuydy M, Ravaud A . Combination of gemcitabine and doxorubicin in rapidly progressive metastatic renal cell carcinoma and/or sarcomatoid renal cell carcinoma. Oncology. 2011; 80(3-4):214-8. DOI: 10.1159/000329078. View

Volpe A, Novara G, Antonelli A, Bertini R, Billia M, Carmignani G . Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. BJU Int. 2011; 110(1):76-83. DOI: 10.1111/j.1464-410X.2011.10690.x. View

Chahoud J, Msaouel P, Ross J, McCormick B, Bathala T, Gao J . Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. 2020; 39(2):134.e9-134.e16. DOI: 10.1016/j.urolonc.2020.10.019. View

Blum K, Gupta S, Tickoo S, Chan T, Russo P, Motzer R . Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol. 2020; 17(12):659-678. PMC: 7551522. DOI: 10.1038/s41585-020-00382-9. View

El Mouallem N, Smith S, Paul A . Sarcomatoid renal cell carcinoma: Biology and treatment advances. Urol Oncol. 2018; 36(6):265-271. DOI: 10.1016/j.urolonc.2017.12.012. View

Quhal F, Mori K, Fajkovic H, Remzi M, Shariat S, Schmidinger M . Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis. Curr Opin Urol. 2021; 32(1):61-68. DOI: 10.1097/MOU.0000000000000940. View

Haas N, Lin X, Manola J, Pins M, Liu G, McDermott D . A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 2011; 29(2):761-7. PMC: 3566570. DOI: 10.1007/s12032-011-9829-8. View

Lauer S, Zhou M, Master V, Osunkoya A . Chromophobe renal cell carcinoma with sarcomatoid differentiation: a clinicopathologic study of 14 cases. Anal Quant Cytopathol Histpathol. 2013; 35(2):77-84. View

Shuch B, Amin A, Armstrong A, Eble J, Ficarra V, Lopez-Beltran A . Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol. 2014; 67(1):85-97. DOI: 10.1016/j.eururo.2014.04.029. View

10.

Chen C, Croom N, Simko J, Stohr B, Chan E . Differential immunohistochemical and molecular profiling of conventional and aggressive components of chromophobe renal cell carcinoma: pitfalls for diagnosis. Hum Pathol. 2021; 119:85-93. DOI: 10.1016/j.humpath.2021.11.003. View

11.

Amin M, Paner G, Alvarado-Cabrero I, Young A, Stricker H, Lyles R . Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol. 2008; 32(12):1822-34. DOI: 10.1097/PAS.0b013e3181831e68. View

12.

Motzer R, Jonasch E, Boyle S, Carlo M, Manley B, Agarwal N . NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. J Natl Compr Canc Netw. 2020; 18(9):1160-1170. PMC: 10191771. DOI: 10.6004/jnccn.2020.0043. View

13.

Bakouny Z, Braun D, Shukla S, Pan W, Gao X, Hou Y . Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021; 12(1):808. PMC: 7865061. DOI: 10.1038/s41467-021-21068-9. View

14.

Przybycin C, Cronin A, Darvishian F, Gopalan A, Al-Ahmadie H, Fine S . Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution. Am J Surg Pathol. 2011; 35(7):962-70. DOI: 10.1097/PAS.0b013e31821a455d. View

15.

Motzer R, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K . Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(1):71-90. PMC: 10191161. DOI: 10.6004/jnccn.2022.0001. View

16.

Casuscelli J, Becerra M, Seier K, Manley B, Benfante N, Redzematovic A . Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series. Clin Genitourin Cancer. 2019; 17(5):373-379.e4. PMC: 6790280. DOI: 10.1016/j.clgc.2019.06.011. View

17.

Cheville J, Lohse C, Zincke H, Weaver A, Blute M . Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003; 27(5):612-24. DOI: 10.1097/00000478-200305000-00005. View

18.

Moch H, Ohashi R . Chromophobe renal cell carcinoma: current and controversial issues. Pathology. 2020; 53(1):101-108. DOI: 10.1016/j.pathol.2020.09.015. View

19.

Wu Y, Kwon Y, Labib M, Foran D, Singer E . Magnetic Resonance Imaging as a Biomarker for Renal Cell Carcinoma. Dis Markers. 2015; 2015:648495. PMC: 4644550. DOI: 10.1155/2015/648495. View

20.

Alaghehbandan R, Przybycin C, Verkarre V, Mehra R . Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates. Asian J Urol. 2022; 9(1):1-11. PMC: 8841285. DOI: 10.1016/j.ajur.2021.11.010. View